Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference
December 02, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City
October 27, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst...
Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting
October 20, 2014 07:15 ET
|
Ohr Pharmaceutical, Inc.
Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes
Regression of the SHRM Biomarker in Wet-AMD and Vision Improvement is Consistent...
Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD
October 14, 2014 07:15 ET
|
Ohr Pharmaceutical, Inc.
Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months
Phase III Trials to Commence in the First Half of 2015
NEW YORK, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ohr...
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting
October 07, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual...
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting
September 09, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II...
Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study
August 13, 2014 08:30 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study...
Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
August 11, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops...
Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference
August 08, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will...
Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists
August 07, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating...